Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer
ObjectiveThis study a to evaluate the cost-effectiveness of ramucirumab plus paclitaxel as a switch maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer, from the perspective of the Chinese healthcare system, to guide clinical decision-making and r...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Frontiers Media S.A.
2026-02-01
|
| سلاسل: | Frontiers in Oncology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1713870/full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|